Adamas to Host Conference Call and Webcast to Provide Company Update
December 22 2015 - 5:24PM
Call Scheduled for Wednesday, December 23 at 8:00
a.m. Eastern Time
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that
Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of
Adamas, will host a conference call and webcast on Wednesday,
December 23, 2015, at 8:00 a.m. ET/ 5:00 a.m. PT, to provide a
company update.
|
|
Dial-in Information |
|
U.S./Canada Dial-in Number: |
(844) 215-3280 |
International Dial-In Number: |
(484) 747-6383 |
Conference ID: |
15542042 |
|
|
Interested parties may access a live audio webcast of the
conference call via the Adamas Pharmaceutical website at
http://ir.adamaspharma.com/events.cfm. A replay of the call
will be available on the Adamas website later in the day. The
replay will be available for approximately one month following the
call.
About Adamas PharmaceuticalsAdamas
Pharmaceuticals, Inc. is driven to improve the lives of those
affected by chronic disorders of the central nervous system.
The company seeks to achieve this by modifying the pharmacokinetic
profiles of approved drugs to create novel therapeutics for use
alone and in fixed-dose combination products. Adamas is
currently developing ADS-5102, its lead wholly owned product
candidate, for the treatment of levodopa-induced dyskinesia
associated with Parkinson's disease and for the treatment of major
symptoms associated with multiple sclerosis in patients with
walking impairment. The company's portfolio also includes
Namzaric™ and Namenda XR®, two approved products with Forest
Laboratories Holdings Limited, an indirect wholly owned subsidiary
of Allergan plc. Forest is responsible for marketing both products
in the United States under an exclusive license from Adamas. For
more information, please visit www.adamaspharma.com.
Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co.
KGaA.
For questions, please contact:
Julie Wood
Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
Phone: 510-450-3528
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Sep 2023 to Sep 2024